Clinical Development FDA Protein Expression 
Alta Sciences
APRIL 17, 2024
Food and Drug Administration (FDA) as a nasal spray called esketamine, for treatment-resistant depression. They work by binding to specific sequences of nucleotides present within the mRNA structure and can induce mechanisms that either decrease, restore, or modify protein expression. Asia, and Europe.
The Pharma Data
DECEMBER 29, 2020
(NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx ® plant cell-based protein expression system, and Chiesi Global Rare Diseases , a business unit of Chiesi Farmaceutici S.p.A.,
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
MARCH 8, 2021
VLA15 is the only active Lyme disease vaccine candidate in clinical development today, and covers six serotypes that are prevalent in North America and Europe. This investigational multivalent protein subunit vaccine targets the outer surface protein A (OspA) of Borrelia, an established mechanism of action for a Lyme disease vaccine.
Drug Target Review
SEPTEMBER 10, 2024
In our experience, reaching a rapid drug substance material delivery to support toxicology studies is becoming a major milestone on the Phase I CMC clinical development path (Figure 1). 1 The concept of in-silico models as surrogate for animal models is also an option for drug developers to generate initial safety data.
The Pharma Data
JANUARY 13, 2021
CD40-ligand is a protein expressed on the surface of activated T lymphocytes that mediates T cell helper function. TNX-801 , live horsepox virus vaccine for percutaneous administration, is in development to protect against smallpox and monkeypox. 175:1091-1101 (1992) 2 Karpusas, M et al., International Immunol. (11):1583
The Pharma Data
DECEMBER 8, 2020
Now poised to advance a robust therapeutics pipeline to clinical development, Nuance will use the funds for ongoing R&D of existing products and business development of potential new assets. Pear’s reSET, reSET-O and Somryst are the first PDTs to receive FDA approval for treating disease. Sigilon Therapeutics .
The Pharma Data
JULY 21, 2021
Positive top-line results have already been reported for two Phase 2 clinical trials of VLA15 in over 800 healthy adults. VLA15 is the only active Lyme disease vaccine candidate in clinical development today, and covers six serotypes that are prevalent in North America and Europe. About VLA15.
Expert insights. Personalized for you.
52 
Let's personalize your content